• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Navidea Biopharmaceuticals makes board of directors changes

September 17, 2021 By Sean Whooley

Navidea BiopharmaceuticalsNavidea Biopharmaceuticals (NYSE:NAVB) announced today that it made a number of changes on its board of directors.

Dublin, Ohio–based Navidea ‘s chair of the board and director S. Kathryn Rouan, along with director Claudine Bruck, retired from those positions, effective immediately.

The board appointed Alexander L. Cappello and John K. Scott, Jr., both existing members of the board, as the chair and vice chair of the board, respectively, according to a news release. The changes were announced following the company’s 2021 annual meeting of stockholders.

Additionally, Cappello was appointed to the company’s audit committee alongside existing members Amit Bhalla (chair) and Malcolm Witter. The board appointed both Cappello and Scott to the compensation, nominating and governance (CNG) committee and appointed Witter as chair of that committee.

“We thank both Kathy and Claudine for their service on the board and the valuable insights they have provided over the years,” Navidea CEO Jed Latkin said in the release. “With a combined 60 years of experience in the clinical space their contributions helped shape both the diagnostic and therapeutic direction of the company. We wish them the best in their future endeavors.”

Navidea develops precision immunodiagnostic agents and immunotherapeutics, including dextran-based drug delivery vehicles deliver potent drugs to the cells where the virus is multiplying, targeting specific macrophages that replicate.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Immunotherapy, Pharmaceuticals Tagged With: Navidea Biopharmaceuticals, Personnel, Personnel Moves

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS